S&P 500   4,960.70 (-0.30%)
DOW   38,489.57 (-0.19%)
QQQ   424.34 (-0.70%)
AAPL   181.85 (+0.16%)
MSFT   399.70 (-0.77%)
META   467.76 (-0.74%)
GOOGL   142.05 (+0.66%)
AMZN   168.21 (+0.68%)
TSLA   193.43 (-0.17%)
NVDA   677.87 (-2.40%)
NIO   6.06 (+1.68%)
AMD   163.62 (-1.25%)
BABA   75.96 (+3.86%)
T   16.99 (+0.47%)
F   12.15 (-0.82%)
MU   80.39 (-0.40%)
CGC   3.36 (-5.08%)
GE   148.29 (-0.22%)
DIS   108.14 (-1.19%)
AMC   4.61 (-1.07%)
PFE   27.54 (-0.18%)
PYPL   57.96 (-1.14%)
XOM   104.30 (+1.51%)
S&P 500   4,960.70 (-0.30%)
DOW   38,489.57 (-0.19%)
QQQ   424.34 (-0.70%)
AAPL   181.85 (+0.16%)
MSFT   399.70 (-0.77%)
META   467.76 (-0.74%)
GOOGL   142.05 (+0.66%)
AMZN   168.21 (+0.68%)
TSLA   193.43 (-0.17%)
NVDA   677.87 (-2.40%)
NIO   6.06 (+1.68%)
AMD   163.62 (-1.25%)
BABA   75.96 (+3.86%)
T   16.99 (+0.47%)
F   12.15 (-0.82%)
MU   80.39 (-0.40%)
CGC   3.36 (-5.08%)
GE   148.29 (-0.22%)
DIS   108.14 (-1.19%)
AMC   4.61 (-1.07%)
PFE   27.54 (-0.18%)
PYPL   57.96 (-1.14%)
XOM   104.30 (+1.51%)
S&P 500   4,960.70 (-0.30%)
DOW   38,489.57 (-0.19%)
QQQ   424.34 (-0.70%)
AAPL   181.85 (+0.16%)
MSFT   399.70 (-0.77%)
META   467.76 (-0.74%)
GOOGL   142.05 (+0.66%)
AMZN   168.21 (+0.68%)
TSLA   193.43 (-0.17%)
NVDA   677.87 (-2.40%)
NIO   6.06 (+1.68%)
AMD   163.62 (-1.25%)
BABA   75.96 (+3.86%)
T   16.99 (+0.47%)
F   12.15 (-0.82%)
MU   80.39 (-0.40%)
CGC   3.36 (-5.08%)
GE   148.29 (-0.22%)
DIS   108.14 (-1.19%)
AMC   4.61 (-1.07%)
PFE   27.54 (-0.18%)
PYPL   57.96 (-1.14%)
XOM   104.30 (+1.51%)
S&P 500   4,960.70 (-0.30%)
DOW   38,489.57 (-0.19%)
QQQ   424.34 (-0.70%)
AAPL   181.85 (+0.16%)
MSFT   399.70 (-0.77%)
META   467.76 (-0.74%)
GOOGL   142.05 (+0.66%)
AMZN   168.21 (+0.68%)
TSLA   193.43 (-0.17%)
NVDA   677.87 (-2.40%)
NIO   6.06 (+1.68%)
AMD   163.62 (-1.25%)
BABA   75.96 (+3.86%)
T   16.99 (+0.47%)
F   12.15 (-0.82%)
MU   80.39 (-0.40%)
CGC   3.36 (-5.08%)
GE   148.29 (-0.22%)
DIS   108.14 (-1.19%)
AMC   4.61 (-1.07%)
PFE   27.54 (-0.18%)
PYPL   57.96 (-1.14%)
XOM   104.30 (+1.51%)
NASDAQ:INMD

InMode (INMD) Stock Price, News & Analysis

$20.68
-0.29 (-1.38%)
(As of 12:04 PM ET)
Today's Range
$20.44
$20.86
50-Day Range
$20.78
$26.49
52-Week Range
$18.57
$48.25
Volume
1.00 million shs
Average Volume
1.80 million shs
Market Capitalization
$1.74 billion
P/E Ratio
8.99
Dividend Yield
N/A
Price Target
$33.00

InMode MarketRank™ Stock Analysis

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
60.0% Upside
$33.00 Price Target
Short Interest
Bearish
10.97% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of InMode in the last 14 days
Based on 22 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
6.70%
From $2.24 to $2.39 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.70 out of 5 stars

Medical Sector

887th out of 1,856 stocks

Electromedical Equipment Industry

9th out of 38 stocks


INMD stock logo

About InMode Stock (NASDAQ:INMD)

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

INMD Stock Price History

INMD Stock News Headlines

InMode: The Inefficacy Of A Company's Investment Strategy
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
UBS Group Boosts InMode (NASDAQ:INMD) Price Target to $26.00
Barclays Raises InMode (NASDAQ:INMD) Price Target to $34.00
InMode Ltd. (INMD) Sued After Report of Severe Discounting- Hagens Berman
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
InMode Ltd. (INMD) Q4 2023 Earnings Call Transcript
InMode Full Year 2023 Earnings: EPS Beats Expectations
InMode Ltd. (NASDAQ:INMD) Q4 2023 Earnings Call Transcript
InMode Q4 Results Top Estimates; Guides FY24 Adj. EPS Above Estimates
InMode Ltd (154.BE)
InMode Q4 2023 Earnings Preview
See More Headlines
Receive INMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMode and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/13/2024
Today
2/21/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:INMD
Fax
N/A
Employees
480
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$33.00
High Stock Price Target
$61.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+57.4%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$197.92 million
Pretax Margin
44.30%

Debt

Sales & Book Value

Annual Sales
$492.05 million
Cash Flow
$2.03 per share
Book Value
$6.68 per share

Miscellaneous

Free Float
78,170,000
Market Cap
$1.76 billion
Optionable
Optionable
Beta
2.22

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Yair Malca (Age 46)
    Chief Financial Officer
    Comp: $474k
  • Mr. Alon Yaari
    Vice President of Operations
  • Dr. Michael Kreindel (Age 56)
    CTO & Director
    Comp: $221k
  • Ms. Nava Tal-Launer
    Chief Information Officer
  • Mr. Shakil Lakhani (Age 41)
    President of North America
    Comp: $2.97M
  • Mr. Moshe Mizrahy (Age 71)
    Chairman & CEO
    Comp: $216k
  • Dr. Spero Theodorou M.D. (Age 52)
    Chief Medical Officer
    Comp: $1.84M














INMD Stock Analysis - Frequently Asked Questions

Should I buy or sell InMode stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for InMode in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INMD, but not buy additional shares or sell existing shares.
View INMD analyst ratings
or view top-rated stocks.

What is InMode's stock price target for 2024?

5 brokers have issued 1 year price targets for InMode's shares. Their INMD share price targets range from $22.00 to $61.00. On average, they expect the company's share price to reach $33.00 in the next twelve months. This suggests a possible upside of 60.0% from the stock's current price.
View analysts price targets for INMD
or view top-rated stocks among Wall Street analysts.

How have INMD shares performed in 2024?

InMode's stock was trading at $22.24 on January 1st, 2024. Since then, INMD stock has decreased by 7.3% and is now trading at $20.62.
View the best growth stocks for 2024 here
.

When is InMode's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our INMD earnings forecast
.

How were InMode's earnings last quarter?

InMode Ltd. (NASDAQ:INMD) issued its quarterly earnings data on Tuesday, February, 13th. The healthcare company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.05. The healthcare company had revenue of $126.80 million for the quarter, compared to analyst estimates of $124.77 million. InMode had a net margin of 40.22% and a trailing twelve-month return on equity of 29.80%. The company's revenue was down 5.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.69 EPS.

When did InMode's stock split?

Shares of InMode split on Thursday, September 30th 2021. The 2-1 split was announced on Friday, September 17th 2021. The newly created shares were issued to shareholders after the market closes on Monday, September 27th 2021. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What guidance has InMode issued on next quarter's earnings?

InMode updated its FY24 earnings guidance on Tuesday, February, 13th. The company provided earnings per share guidance of $2.53-2.57 for the period, compared to the consensus estimate of $2.46. The company issued revenue guidance of $495-505 million, compared to the consensus revenue estimate of $499.20 million.

What is Moshe Mizrahy's approval rating as InMode's CEO?

1 employees have rated InMode Chief Executive Officer Moshe Mizrahy on Glassdoor.com. Moshe Mizrahy has an approval rating of 100% among the company's employees. This puts Moshe Mizrahy in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of InMode own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InMode investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Micron Technology (MU), AbbVie (ABBV), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), DocuSign (DOCU) and PayPal (PYPL).

When did InMode IPO?

(INMD) raised $75 million in an initial public offering (IPO) on Thursday, August 8th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. ​Barclays, UBS Investment Bank and Canaccord Genuity acted as the underwriters for the IPO and Baird was co-manager.

Who are InMode's major shareholders?

InMode's stock is owned by a number of institutional and retail investors. Top institutional investors include Meitav Investment House Ltd. (2.34%), LSV Asset Management (2.34%), Boston Trust Walden Corp (1.75%), DDD Partners LLC (1.48%), Nuveen Asset Management LLC (1.16%) and Migdal Insurance & Financial Holdings Ltd. (1.08%).

How do I buy shares of InMode?

Shares of INMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does InMode have any subsidiaries?
The following companies are subsidiares of InMode: Guangzhou InMode Medical Technology Ltd., InMode Asia Limited., InMode India Private Limited, InMode Japan KK, InMode M.D. Ltd., Invasix Corp., Invasix Iberia S.L., Invasix Inc., and Invasix UK Ltd..
Read More
This page (NASDAQ:INMD) was last updated on 2/21/2024 by MarketBeat.com Staff